In addition, KRAS mutations have been reported in 24% to 50% of inflammatory bowel disease (IBD)–associated SBAs,6,8,29 suggesting that the lack of KRAS point mutations is more likely related to the SB-PCC histology than to IBD-related etiology. Here, KRAS is linked to inflammatory bowel disease.